


# ALK Inhibitor – Mechanism



LEERINK SWANN



- **ALK Malfunction**
  - Wild type signaling dysfunction
  - Point mutations
  - Amplifications
  - Translocations and inversions – fusion ALK

Cancer Type	ALK Expression	% ALK Positive
Lymphoma (ALCL, DLBCL, IMT)	Fusion NPM-ALK	60%
Neuroblastoma	Point mutation	40%
NSCLC	Fusion EML4-ALK	5%
Colorectal Cancer	Fusion EML4-ALK	2.4%
Breast Cancer	Fusion EML4-ALK	2.4%